Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1861291#aggregation> ?p ?o. }
Showing items 1 to 36 of
36
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B418956.
- aggregation creator B418957.
- aggregation creator B418958.
- aggregation creator B418959.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1861291.bibtex.
- aggregation hasFormat 1861291.csv.
- aggregation hasFormat 1861291.dc.
- aggregation hasFormat 1861291.didl.
- aggregation hasFormat 1861291.doc.
- aggregation hasFormat 1861291.json.
- aggregation hasFormat 1861291.mets.
- aggregation hasFormat 1861291.mods.
- aggregation hasFormat 1861291.rdf.
- aggregation hasFormat 1861291.ris.
- aggregation hasFormat 1861291.txt.
- aggregation hasFormat 1861291.xls.
- aggregation hasFormat 1861291.yaml.
- aggregation isPartOf urn:issn:0091-2700.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma".
- aggregation abstract "Inhaled corticosteroids, such as fluticasone propionate (FP) and ciclesonide (CIC), are commonly used for the treatment of asthma. The objectives of this study were to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of FP and a pharmacologically active metabolite of CIC (desisobutyryl-ciclesonide [Des-CIC]) using a nonlinear mixed-effects modeling approach, to investigate selected covariate effects on PK and PD parameters of FP and Des-CIC, and to assess the systemic effects of FP and CIC on serum cortisol suppression in patients with persistent asthma. This was a randomized, double-blind, placebo-controlled, double-dummy, 5-period, crossover, multicenter clinical study. A total of 32 patients were enrolled and given basic asthma medication (salmeterol 50 mu g twice per day [BID] and CIC 160 mu g daily in the evening) through the entire study. During crossover periods, patients were given placebo or CIC 160 mu g BID (ex actuator), CIC 320 mu g BID (ex actuator), FP 220 mu g BID (ex actuator), or FP 440 mu g BID (ex actuator). The FP and Des-CIC PK were described using a 1-compartment and a 2-compartment linear model with first-order absorption process. The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively. The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L. Gender was a significant covariate on the maximum cortisol release rate (male, 3440 mu g/h; female, 4310 mu g/h). The CIC showed the least serum cortisol suppression of the tested dosing regimens.".
- aggregation authorList BK739637.
- aggregation endPage "1127".
- aggregation issue "10".
- aggregation startPage "1118".
- aggregation volume "50".
- aggregation aggregates 1861363.
- aggregation isDescribedBy 1861291.
- aggregation similarTo 0091270009354994.
- aggregation similarTo LU-1861291.